Sonam Puri, MD
Dr. Sonam Puri is a thoracic oncologist and Clinical Research Medical Director at the Moffitt Cancer Center in Tampa, Florida. In her role there, she treats patients with thoracic malignancies including malignant pleural mesothelioma, non-small cell lung cancer, and small cell lung cancer.[1]
Dr. Puri works to improve patient outcomes through novel treatments beyond chemotherapy and surgery. She is also actively engaged in improving the diversity and the equitability of clinical trial treatment. Speaking of the importance of these efforts, she says, “There are many, many barriers to treatment when we’re trying to recruit patients to clinical trials. But my hope is that, in the near future, we’re able to get rid of those barriers and have these newer treatments open for everybody.”[2]
Education and Career
Dr. Puri earned her medical degree from Pandit B.D Sharma PGIMS Rohtak, Haryana. She then completed her internship and residency in Internal Medicine at the University of Connecticut Health Center in Farmington, Connecticut, after which she completed a fellowship in Hematology and Oncology at H. Lee Moffitt Cancer Center and Research Institute/ University of South Florida in Tampa, Florida.[1]
Her background includes experience as an Assistant Professor in the Division of Oncology, Department of Medicine at the University of Utah and as an active member of the Lung Cancer Disease Center of Excellence at the Huntsman Cancer Institute before moving on to her current position at Moffitt Cancer Center.
Professional Memberships and Activities
Dr. Puri is a member of several national and international professional organizations including the American Society of Medical Oncology, the Southwest Oncology Group, the Society of Immunotherapy of Cancer, and the International Association of Study of Lung Cancer, where she serves as a member of the membership committee.[1]
Research
Dr. Puri’s research interests include clinical research in thoracic malignancies, with an emphasis on immunotherapy, targeted therapy, and other novel treatment strategies for non-small and small cell lung cancer and malignant pleural mesothelioma.[1]
Some of the works she has co-authored include:[1]
- Genetic Epidemiology of Lung Cancer Consortium, Akerley W (2023). A rare FGF5 candidate variant (rs112475347) for predisposition to nonsquamous, nonsmall-cell lung cancer. Int J Cancer. Cannon-Albright LA, Teerlink CC, Stevens J, Facelli JC, Carr SR, Allen-Brady K, Puri S, Bailey-Wilson JE, Musolf AM,
- Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data. Cancers (Basel), 14(3). Sama S, Kerrigan K, Sinnott JA, Puri S, Akerley W, Haaland B, Patel S (2023).
- Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer. Cancer Treat Res Commun, 35, 100686. Wang X, Kerrigan K, Puri S, Shen J, Akerley W, Haaland B (2022).
- TERAVOLT study group (2022). A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry. J Thorac Oncol, 17, 661-674. Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Blaquier JB, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Garrido P, Khan H, Baggi A, Mascaux C, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Mtivier AC, Falchero L, Felip E, Genova C, Mazieres J, Tapan U, Brahmer J, Bria E, Puri S, Popat S, Reckamp KL, Morgillo F, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Avrillon V, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Barlesi F, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V,
- A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern. JTO Clin Res Rep, 3(3), 100280. Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, Patel S (2022).
- Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget, 12(25), 2449-2458. Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, Khan H, Mamdani H, Nagasaka M, Puri S, Liu SV, Korn WM, Nieva JJ (2021).
